Verseon Corporation (“Verseon” or the “Company”)
Verseon Corporation, (AIM:VSN) confirms that all resolutions put to shareholders at the Company’s Annual General Meeting held on 20 April 2016 at 14:00 PDT (22:00 BST) were duly passed.
For further information
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Cenkos Securities (NOMAD and Broker)||+44 (0) 20 7397 8900|
|Christopher Golden / Mark Connelly|
|Abchurch Communications Ltd (PR Advisers)||+44 (0) 20 7398 7719|
|Jamie Hooper / Alex Shaw / Abbie Warner|
Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.